dantrolene sodium
Small molecule
dantrolene sodium is one of 7 small molecule programs targeting Wolfram syndrome. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Wolfram Syndrome
#DrugCompanyPhaseTrials
1Januvia
ZZydus Therapeutics Inc.
Phase 3
Acetadote
AArbor Pharmaceuticals, Inc.
Phase 3
Ferriprox
Chiesi Farmaceutici S.p.A.Phase 3
Mounjaro
Eli LillyPhase 2
AMX0035
AAmylyx Pharmaceuticals Inc.
Phase 2
Byetta
AstraZenecaPreclinical
dantrolene sodium
WWashington University School of Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for dantrolene sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]